Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 5

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 income (loss) 
    $3,543,122  
    $(54,931)
  
    Adjustments to reconcile net income (loss) to net cash used in operating activities: 

    Payment of operating costs through promissory note 
     83,676  
     — 
  
    Interest earned on cash and investments held in Trust Account 
     (4,005,966) 
     — 
  
    Changes in operating assets and liabilities: 

    Prepaid expenses 
     (48,904) 
     (60,000)
  
    Accounts payable and accrued expenses 
     70,173  
     — 
  
    Net cash used in operating activities 
     (357,899) 
     (114,931)

    Cash Flows from Investing Activities: 

    Investment of cash into Trust Account 
     (231,150,000) 
     — 
  
    Net cash used in investing activities 
     (231,150,000) 
     — 

    Cash Flows from Financing Activities: 

    Proceeds from sale of Units, net of underwriting discounts paid 
     228,850,000  
     — 
  
    Proceeds from issuance of Class B ordinary shares to Sponsor 
     —  
     35,000 
  
    Proceeds from promissory note - related party 
     —  
     374,955 
  
    Proceeds from sale of Private Placement Units 
     3,200,000  
     — 
  
    Expenses paid by Sponsor under share subscription receivable 
     354,175  
     — 
  
    Repayment of promissory note - related party 
     (900,000) 
     (189,865)
  
    Payment of offering costs 
     3,195  
     (87,061)
  
    Net cash provided by financing activities 
     231,507,370  
     133,029 

    Net Change in Cash 
     (529) 
     18,098 
  
    Cash – Beginning of period 
     1,351  
     — 
  
    Cash – End of period 
    $822  
    $18,098 

    Supplemental disclosure of cash flow information: 

    Share subscription receivable 
    $1,100,000